Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Fasinumab · REGN-475, SAR-164877

Monoclonal antibody · Antagonist of nerve growth factor (NGF) · developed by Regeneron Pharmaceuticals

Phase 3 Most advanced trial (none active)
2 Registered trials

What is Fasinumab?

Fasinumab is a monoclonal antibody that binds nerve growth factor (NGF). It is studied in osteoarthritis of the knee and hip.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
REGN-475, SAR-164877
Drug type
Monoclonal antibody
Targets
nerve growth factor (NGF)
Mechanism
Antagonist of nerve growth factor (NGF)
Therapy area
Musculoskeletal
Developer
Regeneron Pharmaceuticals
In trials of
TEVA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
11T51Q3082

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02683239 Phase 3 Osteoarthritis of the Knee or Hip Completed TEVA
NCT03491904 Phase 1 Osteoarthritis, Knee Completed TEVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Osteoarthritis of the Knee or HipOsteoarthritis, HipOsteoarthritis, Knee

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.